Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity

@article{Montaudi2011MethotrexateIP,
  title={Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity},
  author={H. Montaudi{\'e} and E. Sbidian and C. Paul and A. Maza and A. Gallini and S. Aractingi and F. Aubin and H. Bachelez and B. Cribier and P. Joly and D. Jullien and M. Le Ma{\^i}tre and L. Misery and M. Richard and J. Ortonne},
  journal={Journal of the European Academy of Dermatology and Venereology},
  year={2011},
  volume={25}
}
Background/Aim  To define practical use and to specify the ideal method for monitoring the liver toxicity of MTX in the management of psoriasis. 

Paper Mentions

Interventional Clinical Trial
This study is a prospective, single blinded, randomized, pilot study to compare the effectiveness and safety profile of oral versus subcutaneous route of administration of… Expand
ConditionsPsoriasis Vulgaris
InterventionDrug
Assessment of methotrexate hepatotoxicity in psoriasis patients: a prospective evaluation of four serum fibrosis markers
TLDR
Low‐dose oral methotrexate is an effective immunosuppressive therapy for chronic plaque psoriasis, however, its use is hampered by the risk of liver fibrosis. Expand
Current practice of methotrexate use for psoriasis: results of a worldwide survey among dermatologists
TLDR
Despite its widespread use in psoriasis therapy, dermatologists' practice regarding the use of methotrexate has not been investigated on global scale. Expand
Evidence‐based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists
TLDR
There is a high level of heterogeneity regarding the practical use of conventional systemic treatment in psoriasis and the need to select patients suitable for this type of treatment based on their prior Psoriasis history. Expand
Is methotrexate hepatotoxicity associated with cumulative dose? A systematic review and meta‐analysis
TLDR
This work sought to synthesise the published literature to evaluate the association between methotrexate hepatotoxicity and cumulative dose. Expand
A consensus report on appropriate treatment optimization and transitioning in the management of moderate‐to‐severe plaque psoriasis
TLDR
There is limited information on systemic and biological treatment optimization and transitioning in routine clinical practice and there is a need for more research into this area. Expand
A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis
TLDR
Etanercept plus methotrexate combination therapy has not been adequately investigated in psoriasis and the safety and effectiveness of this combination therapy is still under investigation. Expand
Methotrexate vs. fumaric acid esters in moderate‐to‐severe chronic plaque psoriasis: data registry report on the efficacy under daily life conditions
Objective  To compare the clinical efficacy of methotrexate (MTX) vs. fumaric acid esters (FAE) in psoriasis treated under daily life conditions.
Methotrexate: Underused and Ignored?
TLDR
International data on medication utilization suggest that this drug is rarely used in clinical practice for an indication of Crohn’s disease, and the potential reasons for the underuse are investigated. Expand
TT genotype of rs10036748 in TNIP1 shows better response to methotrexate in a Chinese population: a prospective cohort study
Methotrexate (MTX) is an efficacious treatment for psoriasis; however, its widespread application is limited by its unpredictable efficacy.
Validity of noninvasive markers of methotrexate‐induced hepatotoxicity: a retrospective cohort study
Methotrexate is a cost‐effective systemic treatment for moderate‐to‐severe psoriasis, but the perceived risk of associated liver fibrosis prevents optimal use. Procollagen III aminoterminalExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 34 REFERENCES
Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial
TLDR
No previous studies comparing methotrexate and ciclosporin for moderate to severe plaque psoriasis had been performed, so this was the first study of its kind. Expand
Evidence‐based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists
TLDR
There is a high level of heterogeneity regarding the practical use of conventional systemic treatment in psoriasis and the need to select patients suitable for this type of treatment based on their prior Psoriasis history. Expand
Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis
TLDR
The once-weekly treatment with methotrexate for moderate to severe chronic plaque psoriasis and mycophenolate mofetil for inflammation has shown promising results in animal studies. Expand
Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double‐blind, placebo‐controlled trial
TLDR
This data indicates that folate supplementation in methotrexate (MTX)‐treated patients remains controversial and may need to be investigated further to determine its value in patients treated with the drug. Expand
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)
TLDR
This data indicates that once-weekly dosing with adalimumab is a safe and effective treatment for moderate to severe chronic plaque psoriasis in women with atypical immune response to chemotherapy. Expand
Biochemical and biophysical assessment of MTX‐induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan® predicts the absence of significant liver fibrosis
  • M. Berends, J. Snoek, +5 authors J. Drenth
  • Medicine
  • Liver international : official journal of the International Association for the Study of the Liver
  • 2007
TLDR
The Fibroscan® and the Fibrotest are two novel, non‐invasive methods that might be able to assess MTX‐induced hepatic fibrosis in psoriasis patients. Expand
Methotrexate hepatotoxicity in psoriasis. Consideration of liver biopsies at regular intervals.
TLDR
Age of the patient and duration of therapy have been found to be significant factors in those patients receiving only the weekly oral dosage schedule and fibrosis of the liver developed to a degree that contraindicated further treatment with methotrexate. Expand
The value of amino‐terminal propeptide of type III procollagen in routine screening for methotrexate‐induced liver fibrosis: a 10‐year follow‐up
TLDR
Reliable non‐invasive monitoring tests would have considerable importance in patients treated with this drug for skin disease. Expand
Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up.
TLDR
It is shown that diabetic patients are particularly at increased risk of MTX hepatotoxicity, and three patients who developed cirrhosis over two years of standard MTX therapy may represent a subset of psoriatics with increased hepatic susceptibility to MTX. Expand
Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference.
TLDR
A task force of the National Psoriasis Foundation Medical Board achieved a consensus on new updated guidelines for the use of methotrexate in the treatment of psoriasis including specific recommendations on dosing and monitoring. Expand
...
1
2
3
4
...